U.S. Food & Drug Administration: Draft Guidance for Industry and Other Interested Parties
Date: January 23, 2025
The U.S. Food and Drug Administration has issued its first guidance on the use of Artificial Intelligence (AI) for the development of drug and biological products.
This draft guidance, titled ‘Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products,’ has been put together to provide recommendations on the use of AI intended to support a regulatory decision about a drug or biological product’s safety, effectiveness, or quality.
Read here: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological
Explore More News
Launch of Online Training from ACDM
The Association for Clinical Data Management is delighted to announce the launch of Online . . .
Read More
ACDM 2019 Awards Finalists
The Association for Clinical Data Management are delighted to announce the finalists for . . .
Read More
Castor EDC to Sponsor ACDM19
The Association for Clinical Data Management (ACDM) are delighted to announce that Castor . . .
Read More
Danone Nutricia Research to Sponsor ACDM19
The Association for Clinical Data Management (ACDM) are delighted to announce that . . .
Read More
ACDM19 Conference Programme
The Association for Clinical Data Management is delighted to announce the Full Programme . . .
Read More
Record Number of Abstracts Submitted for ACDM19
The deadline for Abstracts for ACDM19 passed on the 30th September and the Association for . . .
Read More
Phastar Sponsor ACDM19
The Association for Clinical Data Management are delighted to announce that PHASTAR are . . .
Read More
Launch of Annual ACDM Awards
The Association for Clinical Data Management are delighted to announce the introduction of . . .
Read More
